Close
Home - Press releases - Ethypharm reinforces its late-stage R&D pipeline with a novel acute treatment of migraine

Do you have
any question?

Contact us
19/05/2021

Ethypharm reinforces its late-stage R&D pipeline with a novel acute treatment of migraine

Saint-Cloud, France – May 19th, 2021 – Ethypharm announces today that it has acquired the exclusive rights for the development, registration and commercialization in the top 5 European markets of a novel celecoxib formulation already approved in the US for the acute treatment of migraine. This agreement confirms Ethypharm’s commitment to patients whose daily life is altered by pain.

Press release

Media enquiries

Please provide a valid state.
Please provide a valid state.
Please provide a valid state.
(+)
Please provide a valid state.
Please provide a valid state.
Please provide a valid state.
*All fields must be filled in

Thank you for your message!
We will examine it with utmost attention and get back to you shortly.